Beijing, China; Cambridge, Massachusetts, United States (December 18^th, 2021) -- CANbridge Pharmaceuticals Inc. (“CANbridge” or “the Company”, stock code: 1228.HK) is a  China-based global  biopharmaceutical company committed to the research, development and commercialization of transformative rare disease therapies. James Xue, Ph.D., Founder, Chairman and CEO of CANbridge, participated in the launch ceremony for the Chinese Red Cross Foundation’s Rare Disease Support Fund, and he was one of the representatives of chief founding members of this fund.

On December 18^th, 2021, the 2021 China Conference on Rare Diseases officially kick-started in Beijing. The conference was guided by the National Health Commission (“NHC”), and the headquarters of the Red Cross Society of China; mainly organized by China Alliance for Rare Diseases, Chinese Red Cross Foundation (“CRCF”), China Pharmaceutical Innovation and Research Development Association, and Chinese Hospital Association; and assisted in organization by the Peking Union Medical College Hospital (“PUMCH”), and the office of the National Cooperation Network in Diagnosis and Treatment for Rare Diseases.

At the launch ceremony, Changjiang Guo, Chairman of the Chinese Red Cross Foundation, awarded the fund’s first batch of supporting enterprises. Jinguo He, Director General of Finance at the NHC, Yanhong Guo, a hospital administration supervisor at the NHC, Peixin Wu, Secretary of the Party Committee at Peking Union Medical College Hospital, and Linkang Li, Executive Director of the China Alliance for Rare Diseases officiated at the launch ceremony for the project, in which the State Lottery Welfare Fund supports the enhancement of China’s diagnostic and treatment capabilities for rare diseases. As one of the chief founding members of the fund, CANbridge took part in the launch ceremony.

James Xue, Ph.D,CANbridge Founder, Chairman of the Board and CEO& LI Linkang ,Executive Director ,China Alliance for Rare Disease

Representative of CANbridge attended the launch ceremony of the Chinese Red Cross Foundation (CRCF) Rare Disease Mutual Assistance Fund

James Xue, Ph.D., Founder, Chairman and CEO of CANbridge, noted that it is a great honor to have participated in launching the Chinese Red Cross Foundation’s Rare Disease Support Fund. It is the corporate social responsibility and major mission of enterprises to push for and assist charitable activities, including those aimed to help rare disease patients. The Company has always been committed to the establishment of a rare disease ecosystem, in order to help perfect the multiple-layer system of protection and benefits for rare disease patients and reduce their families’ burden. Moving forward, we shall collaborate with key stakeholders such as the China Alliance for Rare Diseases and CRCF in initiating a series of assistance campaigns for rare disease patients, so as to push for the development  in the prevention, treatment and protection for rare diseases on a next level.

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. (“CANbridge,” stock code: 1228.HK) is a China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies.

CANbridge has a comprehensive and differentiated pipeline of 13 drug assets with significant market potential, targeting some of the most prevalent rare diseases and rare oncology.

These include Hunter syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme (GBM).

CANbridge strategically combines global collaborations and internal research to build and diversify its drug portfolio and invest in next-generation gene therapy technologies for rare disease treatments. CANbridge global partners include, but are not limited to, Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the University of Massachusetts Medical School (UMass), the University of Washington School of Medicine, LogicBio and Scriptr.

For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.

 Contact:

CANbridge Pharmaceuticals Inc.

ir@canbridgepharma.com

Media:

Deanne Eagle

Planet Communications

deanne@planetcommunications.nyc

917.837.5866